|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
|   |

 |
|

|  |
| --- |
|  |
| News Alert |
| Friday 29th April 2022 |

 |
|  |
|

|  |  |  |
| --- | --- | --- |
|  |  |  |
|  | Three new SSPs introduced for HRT medicines |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  | In response to a significant ongoing disruption affecting three Hormone Replacement Therapy (HRT) medicines, the Department of Health and Social Care (DHSC) have issued three new Serious Shortage Protocols (SSPs).These SSPs, introduced with immediate effect, enable community pharmacists in the UK to supply patients with no more than three months’ worth of these medicines.  The protocols allow for a reduced quantity of the specified medicines to be supplied to help manage the ongoing supply disruption affecting these HRT products.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **SSP number** | **Brand name** | **Generic name** | **SSP** | **SSP Expiry** | **Supporting Information** |
| [**SSP019**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=7e157501e5&e=d19e9fd41c) | Oestrogel Pump-Pack 0.06% gel | Estradiol 0.06% gel (750microgram per actuation) | SSP019: Oestrogel Pump-Pack 0.06% gel | Friday 29 July 2022 | [**SSP019 guide**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=d1832b8af7&e=d19e9fd41c) |
| [**SSP020**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=e89597fe5c&e=d19e9fd41c) | Ovestin 1mg cream | Estriol 0.1% cream | SSP020: Ovestin 1mg cream | Friday 29 July 2022 | [**SSP020 guide**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=01e09f2552&e=d19e9fd41c) |
| [**SSP021**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=ae7e181fa4&e=d19e9fd41c) | Premique Low Dose 0.3mg/1.5mg modified-release tablets | Conjugated oestrogens 300microgram / Medroxyprogesterone 1.5mg modified-release tablet | SSP021: Premique Low Dose 0.3mg/1.5mg modified-release tablets | Friday 29 July 2022 | [**SSP021 guide**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=079c7d2c54&e=d19e9fd41c) |

Pharmacy teams are advised to **read the documentation for SSP019, SSP020 and SSP021 in full and to implement the protocol with immediate effect**. Pharmacists are required to read and comply with the requirements outlined within the individual SSPs and supporting guidance as published on the [**NHSBSA website**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=efe28bff0c&e=d19e9fd41c) for the three HRT products listed above.Contractors will also receive an email to their shared NHSmail account informing them of these SSPs.**Please note, these SSPs may be amended or revoked at any time but are currently due to expire on 29 July 2022 – PSNC will update contractors on any changes.**For further information and guidance please see our news story: [**Three new SSPs introduced for HRT medicines**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=aee5240522&e=d19e9fd41c) |  |
|  |  |  |

 |

 |
|

|  |  |  |
| --- | --- | --- |
|

|  |
| --- |
| Pharmaceutical Services Negotiating Committee **Graphical user interface  Description automatically generated** **Graphical user interface  Description automatically generated** **Graphical user interface  Description automatically generated** 14 Hosier Lane, London, EC1A 9LQTel: 0203 1220 810 | Email: **info@psnc.org.uk**  |
|  |

 |

 |

